EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

Nobuyuki Horita, Yu Fujiwara

New England Journal of Medicine · 18.01.2024 · 390 (3) · 287-288

DOI: 10.1056/nejmc2313778 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 18.01.2024. Verfasst von Nobuyuki Horita und 1 weiteren Autor:innen. Beteiligte Einrichtung: Yokohama City University Hospital, Yokohama, Japan horitano@yokohama-cu.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 1 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editor: In their report on the AEGEAN trial, Heymach et al. (Nov. 2 issue) 1 found that perioperative durvalumab for resectable non–small-cell lung cancer significantly extended event-free survival. In Table 3, the incidence of adverse events leading to discontinuation of durvalumab or placebo was 12.0% (48 of 401) in the durvalumab group and 6.0% (24 of 398) in the placebo group. The authors commented that the treatment “had no detrimental effect on the completion of neoadjuvant chemotherapy or surgery.” However, we noticed a significant between-group difference in these events (P=0.004 by Fisher’s exact test). We then performed a brief . . .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, MonoclonalHumans

Substanzen

durvalumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Yokohama City University Hospital, Yokohama, Japan horitano@yokohama-cu.ac.jp.
  • Roswell Park Comprehensive Cancer Center, New York, NY.

Zitieren

APA

Horita, N., & Fujiwara, Y. (2024). Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer. New England Journal of Medicine, 390(3), 287-288. https://doi.org/10.1056/nejmc2313778

Vancouver

Horita N, Fujiwara Y. Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2024;390(3):287-288. doi:10.1056/nejmc2313778

BibTeX
@article{Horita2024,
  author = {Horita, Nobuyuki and Fujiwara, Yu},
  title = {Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {3},
  pages = {287--288},
  doi = {10.1056/nejmc2313778}
}
Kostenlos starten →